Personalized Precision Care for Cancer — Where Innovation Meets Compassion.
We don't just adopt a single technology—we systematically integrate the world's leading medical resources, innovative technologies, and diverse funding channels. This means you no longer need to navigate multiple institutions in search of the best care. Instead, we offer you a seamless, one-stop international-standard healthcare experience.
We possess Asia's leading, diversified technology portfolio—featuring cutting-edge therapies such as CAR-T, Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Boron Neutron Capture Therapy (BNCT). When one path reaches a bottleneck, we may open another window of hope for you.
We reject a "one-size-fits-all" approach. Guided by the principles of precision medicine, we assemble a Multidisciplinary Team (MDT) of experts to deeply analyze your condition at the genomic level—and craft a truly personalized treatment plan tailored specifically for you.
Where cutting-edge medicine meets heartfelt care—supported by your case management team from day one to full recovery.
Re-engineering Immune Cells to Precisely Target Cancer
Targeted Therapy That Precisely Destroys Cancer Cells from Within
Selective Internal Radiation Therapy (SIRT) — Precisely Targeting Liver Tumors
Targeted Radionuclide Therapy — Precisely Eliminating Cancer Cells
Precision Detonation Inside Cancer Cells to Treat Recurrent Tumors
Correcting the Root Cause of Disease at the Genetic Level
Activating the Immune System to Target Tumor Cells
Precisely eliminate cancer cells using engineered immune cells.
Every life touched by cancer deserves more options and greater hope. This International Center for Precision Oncology is jointly established by Super Hospital and Huali Hainan, dedicated to delivering world-class precision oncology care.
Our core mission is to deliver comprehensive, personalized diagnostic and therapeutic solutions for cancer patients by integrating world-class medical resources, innovative technologies, and diversified funding channels.
We deeply understand that confidence is just as vital as cutting-edge technology when facing illness. Therefore, we have brought together the world's most advanced therapeutic approaches—including CAR-T cell therapy, nuclear medicine therapies, Yttrium-90 (Y90) microsphere therapy, Lutetium-177 (Lu177) radioligand therapy, Boron Neutron Capture Therapy (BNCT), gene therapy, dendritic cell (DC), and immune cell therapies—so that whenever you need them, we can offer more possibilities.
Regenerative Medicine Specialist
Professor Chen specializes in oncology and stem cell technologies, with extensive research and deep expertise in regenerative medicine and cell therapy. His work is dedicated to advancing the clinical translation of cutting-edge cellular therapies. Professor Chen has participated in international clinical trials and translational research in cell therapy, accumulating substantial experience in clinical application, safety evaluation, and optimization of therapeutic efficacy. With profound expertise in precision oncology, Professor Chen is committed to bridging groundbreaking scientific discoveries with real-world clinical practice—to deliver more effective, personalized treatment options for patients.
Precision Oncology Specialist
Dr. Li Dinggang is a member of the International Society of Cryosurgery, a Council Member of the Chinese Society of Biotechnology, a Council Member of the China Chapter of the World Institute of Pain, an Editorial Board Member of the Chinese Journal of Medical Biotechnology, a member of the Beijing Branch of the Chinese Anti-Cancer Association, and a member of the General Surgery Committee of the Beijing Medical Association. With extensive clinical experience in the treatment of solid tumors—including lung, breast, gastric, pancreatic, liver, and head and neck cancers—Dr. Li Dinggang specializes in designing and implementing personalized, multidisciplinary cancer treatment strategies that integrate surgical oncology, tailored chemotherapy regimens, integrative Chinese-Western medicine approaches, gene therapy, minimally invasive Argon-Helium cryoablation, hyperthermia, and biological targeted therapies, always striving to deliver precise, effective, and patient-centered care grounded in the latest advances in oncology.
This is an integrated medical, educational, and research project jointly established by the Boao Lecheng International Medical Tourism Pilot Zone and Sichuan University. The hospital is planned to have 300–500 beds, and its establishment marks a significant breakthrough for the Lecheng Pilot Zone in securing special approval to introduce a renowned public hospital from mainland China.
Also known as the Hainan Boao Investigational Hospital, it is a national regional medical center jointly established by Shanghai and Hainan provinces. As one of the earliest public Grade-A tertiary general hospitals to open in the Boao Lecheng International Medical Tourism Pilot Zone, it is fully operated and managed by Ruijin Hospital of Shanghai. The hospital is dedicated to implementing innovative drug and medical device programs and has already delivered world-class, internationally aligned diagnosis and treatment services to a large number of patients.
It is an innovative platform hospital operating under the pioneering "1+X" model, which has attracted multiple top-tier academician-led expert teams—including those of Academician Li Lanjuan and Academician Wang Chen. The hospital has introduced a significant number of specially approved drugs and medical devices and has successfully performed numerous groundbreaking procedures and therapies, including many first-in-China cases.
Planned and constructed to Grade-A tertiary hospital standards, the facility will offer 600 beds. It aims to become an innovation and translation hub for the healthcare industry and an international gateway for open collaboration. Operating under the "1+X" shared-hospital model, it brings together leading medical experts and focuses on the research, development, and clinical application of cutting-edge medical technologies.
It is a non-profit, comprehensive Grade-A tertiary hospital integrating medical care, research, prevention, and rehabilitation, and serves as a flagship project under the Shandong–Hainan healthcare collaboration initiative. Ten renowned public medical institutions from Shandong Province, including Qilu Hospital of Shandong University and Shandong Provincial Hospital, have joined as the first cohort of expert teams to jointly deliver care to patients.
This is the first project in Hainan by Raffles Medical Group, Singapore's leading private integrated healthcare provider. The hospital will initially focus on obstetrics and gynecology, male reproductive urology, and general specialties, with the goal of establishing itself as a strategic hub within Raffles' healthcare network across China and Southeast Asia—delivering internationally aligned medical services and management standards to patients.
As the flagship healthcare project of The Ritz-Carlton Group, the hospital primarily focuses on the prevention and treatment of cardiovascular and cerebrovascular diseases, chronic disease management, and rehabilitation and wellness care. It is dedicated to building a premium integrated medical service platform that unifies prevention, treatment, rehabilitation, and nursing care—delivering a holistic, high-end health experience.
An international Grade-A tertiary general hospital built to the global Joint Commission International (JCI) standards, the facility specializes in reproductive medicine—offering advanced services such as third-generation in vitro fertilization (IVF)—and has brought in world-class assisted reproductive technology (ART) medical teams from around the globe.
A Grade-A tertiary integrated medical institution distinguished by its focus on "life care and wellness." Its services encompass health promotion, disease prevention, chronic condition management, rehabilitation therapy, and traditional Chinese medicine–based treatments, addressing users' multi-layered, diverse, and personalized health needs.
Shanghai Jiao Tong University School of Medicine Ruijin Hospital Hainan hospital
Knee Osteoarthritis
This therapy is primarily indicated for degenerative knee osteoarthritis—such as cartilage wear and joint inflammation—and involves a single intra-articular injection of umbilical cord-derived mesenchymal stem cells to promote cartilage regeneration and suppress inflammatory responses.
Chronic Obstructive Pulmonary Disease (COPD)
Utilizing internationally advanced autologous airway basal stem cell therapy for COPD, the treatment has successfully achieved reconstruction of functional gas-exchange units and regenerative repair of damaged lung tissue in patients.
West China Lecheng Hospital, Sichuan University
Patients with heart failure and a left ventricular ejection fraction (LVEF) ≤ 40%, classified as NYHA functional class II to IV.
This therapy is indicated for patients with chronic heart failure and a left ventricular ejection fraction (LVEF) ≤ 40% (NYHA class II–IV). It involves intravenous infusion of allogeneic umbilical cord-derived mesenchymal stem cells to promote myocardial microvascular neovascularization and reduce fibrosis.
Bronchiectasis
Regend Therapeutics's proprietary autologous airway basal stem cell therapy can reconstruct the epithelial barrier and significantly improve the local immune-inflammatory microenvironment.
Interstitial Lung Disease (ILD)
In patients with interstitial lung disease (ILD), the lungs undergo progressive fibrosis, leading to destruction of healthy alveoli. Advanced therapy using autologous airway basal stem cells can regenerate new alveolar and bronchial epithelial structures within weeks after treatment.
Graft-versus-Host Disease (GVHD)
The indication is severe graft-versus-host disease (GVHD)—an immune-mediated complication—following bone marrow transplantation. The treatment involves a single intravenous infusion of allogeneic mesenchymal stem cells to modulate the immune response, without the need for HLA matching.
Liver cancer, lung cancer, melanoma, breast cancer, urothelial carcinoma, pancreatic cancer, and others.
This therapy can be used for solid tumors (such as lung cancer and breast cancer) as well as hematologic malignancies. It involves harvesting the patient's dendritic cells (DCs) to manufacture a personalized vaccine that activates tumor-specific T cells to target and kill cancer cells.
Biallelic Mutation-Associated Inherited Retinal Dystrophy
Targeting retinal disease (vision loss) caused by mutations in the RPE65 gene, this therapy delivers a functional copy of the RPE65 gene to retinal cells using an adeno-associated virus (AAV) vector.
Shulan (Boao) Hospital
Interstitial lung disease with progressive fibrosis despite conventional treatment
Pulmonary fibrosis is a severe lung disease with limited clinical treatment options and poor patient prognosis. Menstrual blood-derived mesenchymal stem cells possess multilineage differentiation potential and immunomodulatory properties.
Ciming Boao International Hospital
Premature Ovarian Insufficiency (POI)
Premature ovarian insufficiency (POI) significantly impairs women's reproductive health and quality of life. Umbilical cord-derived mesenchymal stem cell therapy holds promise for restoring ovarian function by improving the local ovarian microenvironment and promoting follicular development.
EBV infection–associated diseases
This technology holds promise as a novel and effective approach for treating EB virus–associated diseases, as Epstein-Barr virus (EBV) is closely linked to the development and progression of various conditions, including nasopharyngeal carcinoma and lymphoma.
Prevention of postoperative recurrence of hepatocellular carcinoma
Activated T lymphocyte therapy is used to prevent postoperative recurrence of hepatocellular carcinoma and improve patient survival rates.
Hainan Yiling Healthy Dental Center
Periodontitis / Patients aged 18 years and older
The treatment involves localized minimally invasive injection of human dental pulp mesenchymal stem cells—possessing advantageous biological properties such as immunomodulation, osteogenesis, and angiogenesis—directly into periodontal defect sites to promote periodontal tissue regeneration.
Mellsser International Medical Center
Liver cirrhosis
Human umbilical cord-derived mesenchymal stem cell therapy for liver cirrhosis aims to improve liver function and promote hepatocyte regeneration.
Rheumatoid Arthritis (RA)
Stem cell therapy for rheumatoid arthritis addresses key clinical challenges in RA management, featuring an innovative approach using umbilical cord-derived mesenchymal stem cells.
We assemble a multidisciplinary team of experts—including specialists in surgical oncology, medical oncology, radiation oncology, radiology, and pathology—for each patient to collaboratively develop the optimal treatment plan.
Through multidisciplinary collaboration, we ensure that treatment plans are scientifically sound, comprehensive, and personalized, delivering the highest quality of care to patients.
